Palbociclib (PD-0332991) HCl

Pfizer辉瑞授权 目录号:S1116

Palbociclib (PD-0332991) HCl Chemical Structure

Molecular Weight(MW): 483.99

Palbociclib (PD-0332991) HCl是一种高度选择性的CDK4/6抑制剂,无细胞试验中IC50分别为11 nM/16 nM。它对CDK1/2/5,EGFR,FGFR,PDGFR,InsR等没有抑制活性。Phase 3。

规格 价格 库存 购买数量  
RMB 902.49 现货
RMB 1406.17 现货
RMB 4670.26 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的8个实验数据:

  • PD-0332991 causes inhibition of proliferation of EAC cells in a dose-dependent manner. Western blots showing the phosphorylation status of pRB at Ser780 and Ser795 after incubation with 125 nmol/L PD-0332991 for 24 and 72 hours. Reduction in cyclin A expression and the expression of RB2 (p130) tumor suppressor 72 hours after PD-0332991 treatment are shown (bottom). Total pRB (RB1) and actin are loading controls and T293 cell lysate (293) is a positive control for total pRB and phospho-pRB (Ph-RB). E, anchorage-independent growth of the 3 cell lines in the presence or absence (Cnt) of 125 nmol/L PD-0332991 for 3 weeks.

    Clin Cancer Res 2011 17(13), 4513-22. Palbociclib (PD-0332991) HCl purchased from Selleck.

    b, c MelJuso cells were treated for 12–48 h with 1 µM Selumetinib or 5 µM Palbociclib and the cells were fixed, stained with propidium iodide and cell cycle distribution was determined by flow cytometry (b) and whole cell extracts were fractionated by SDS-PAGE, transferred onto PVDF membrane and immuno-blotted with the indicated antibodies (c). Data is from a single experiment representative of three separate experiments with similar results. The data in (b) are mean ± S.D. from a single experiment with three replicate dishes of cell per data point; similar results were obtained in two additional experiments

    Cell Mol Life Sci, 2016, 73(4):883-900. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • (A) Percentage of DN3a cells in S-phase (as gated on DAPI profile) from control (Zfp36l1/2fl/fl) and Zfp36l1/2fl/fl; CD2Cre (DCKO) mice, after 1 d of treatment with vector or palbociclib (drug).

    J Immunol, 2016, 197(7):2673-85. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Patient tumor cell sensitivity to combinatorial treatment with histone deacetylase (HDAC)/cyclin-dependent kinase (CDK) inhibitors in 3-D culture. The effect of each drug or drug combination was assessed by fluorescent dye to identify live (green) and dead cells (red). Cells from breast reduction patients were used as non-cancer control in the assay.

    Pharmacogenomics J 2013 13(1), 94-104. Palbociclib (PD-0332991) HCl purchased from Selleck.

  •  

    Cdk4 is upregulated in ARMS and mMSCs transfected with PAX7-FKHR fusion gene (MP7F), and can be specifi cally inhibited. D: IF results showing overexpression of cdk4 in MP7F cells compared to parental mMSCs and reduced expression of cdk4 after treatment of MP7F cells with the cdk4 inhibitor, PD-0332991. E: IF results showing MyoD1 expression in parental mMSCs cells, and MP7F cells untreated and after treatment with the cdk4 inhibitor, PD-0332991.

    Clin Transl Oncol 2012 14(3), 197-206 . Palbociclib (PD-0332991) HCl purchased from Selleck.

    WM3734 melanoma cells were treated by PD-0332991 for 36 hours; melanoma cells treated by Doxorubicin (DXR)  at 0.5 μM is included as a control.

     

     

    Dr. Gao Zhang of University of Pennsylvania. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • Serum-deprived T98G glioma cells are restimulated with serum(FBS) with or without 1 μΜ PD-0332991.

     

     

    Dr. Sabine Paternot and Dr Pierre Roger of IRIBHM, ULB, Brussels. Palbociclib (PD-0332991) HCl purchased from Selleck.

    P16INK4A knockdown in INK4A/ARF-wt human glioma cell LN319 potentiates PDGF-Apromoted anchorage-dependent growth in vitro. Soft agar growth of Ink4a/Arf-deficient mAst and LN444 cells treated with PD0332991. (A) IB analysis. (B) Quantification of soft agar assays. β-actin was used as a loading control in all IB experiments. Data are presented as mean ± s.d. and representative of two independent experiments. **, P < 0.01; ***, P < 0.001

    Dr. Kun-Wei Liu from University of Pittsburgh. Palbociclib (PD-0332991) HCl purchased from Selleck.

产品安全说明书

CDK抑制剂选择性比较

生物活性

产品描述 Palbociclib (PD-0332991) HCl是一种高度选择性的CDK4/6抑制剂,无细胞试验中IC50分别为11 nM/16 nM。它对CDK1/2/5,EGFR,FGFR,PDGFR,InsR等没有抑制活性。Phase 3。
特性 PD-0332991作为有应用前景的工具测定CDK激酶是否具有明显的治疗价值。
靶点
CDK4/CyclinD3 [1]
(Cell-free assay)
CDK4/CyclinD1 [1]
(Cell-free assay)
CDK6/CyclinD2 [1]
(Cell-free assay)
9 nM 11 nM 15 nM
体外研究

PD 0332991 对其他蛋白激酶包括EGFR, FGFR, PGFR, IR等没有抑制效果。 PD 0332991作用于Cdk4时是非ATP竞争性抑制剂。PD 0332991抑制MDA-MB-435乳腺癌细胞,IC50为66 nM,是由于Rb 在Ser780的磷酸化作用下降。PD 0332991抑制胸苷合并到Rb阳性的人类乳腺癌,结肠癌 肺癌,及白血病的DNA中,IC50值为4 nM到0.17 μM。PD 0332991作用于Rb阴性细胞没有抑制效果。PD 0332991作用于MDA-MB-453乳腺癌细胞和结肠-205细胞使细胞积累在G1期。[1]PD 0332991也有效作用于骨髓瘤5T33MM细胞,使细胞对Bortezomib敏感。[2]PD 0332991抑制luminalER-阳性和HER2-增强的乳腺癌细胞系,包括MDA-MB-175 ZR-75-30 CAMA-1 MDA-MB-134 HCC-202 UACC-893 等等。在这些细胞系中,PD 0332991增强Tamoxifen和Trastuzumab 的活性。在MCF7抗Tamoxifen细胞中,PD 0332991也增强tamoxifen 的敏感性。[3] 最新研究显示PD 0332991可以抑制恶性横纹肌样肿瘤(MRT)细胞系包括MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS,且MRT细胞系对PD 0332991敏感性和p16表达呈负相关。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLM13 MVHLbY5ie2ViQYPzZZk> NVrsRpBkOjRiaB?= NWjSSpc6UW6qaXLpeIlwdiCxZjDDSGs1KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhWmJicHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAxOiEQvF2= NHvyXpYzPDZ2MUGwNy=>
COLO205 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXm[FBjPzJiaB?= M3K2ZWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2W|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5yM{[g{txO MYqyOFY1OTFyMx?=
U937 M3TONmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfpO|IhcA>? NWHPdIpuSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|ZYPz[YQh[XNiaX7jc5Jxd3KjdHnvckBw\iCdM1jdeIh6dWmmaX7lJIlvfG9iRF7BJJdqfGhiSVO1NEBw\iByLkG0JO69VQ>? NHrXW5IzPDZ2MUGwNy=>
MOLM13 M2XzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33UO|czKGh? M4HQeGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV;MUVE{KGOnbHzzJIhiemKxcnnu[{BHVFR|IFnUSEBufXSjboSgZZN{\XO|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjB7NjFOwG0> Mln6NlQ3PDFzMEO=
MOLM13 NEHWZVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfFUZE4OiCq NHTHdmxCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JJNwemGoZX7pZk1z\XOrc4ThcpQhcHWvYX6gUW9NVTF|IHPlcIx{KGG|c3Xzd4VlKGG|IHnuZ49zeG:{YYTpc44hd2ZiW{PIYZRpgW2rZHnu[UBqdnSxIFTORUB4cXSqIFnDOVAhd2ZiMD6wPVYh|ryP NVvqWm1kOjR4NEGxNFM>
MDA-MB-435 M1HmPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWKyOEBp M3jieWlEPTB;MD6xOkDPxE1? NVjHTZN[OTV6MEG4N|E>
K562 MVzDfZRwfG:6aXOgRZN{[Xl? MVq5OkBp MkPtSG1UVw>? MXnJR|UxRTJizszN M4i2[|I1PDF5NU[2
DU145 MlHyR5l1d3SxeHnjJGF{e2G7 MVO5OkBp MkTGSG1UVw>? MYrJR|UxRTdwNTFOwG0> NXLkTlBMOjR2MUe1OlY>
MDA-MB-231 M3fGU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fHeFEh|ryP MUSyOEBp NXHBZWlnTE2VTx?= M2jLfGNmdGxiY4njcIUh[XK{ZYP0JIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDheEBIOSCyaHHz[S=> NXHaTHEzOjR2MUe1OlY>
MCF7 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILqT|cyKM7:TR?= MVKyOEBp MXzEUXNQ M3ixNmNmdGxiY4njcIUh[XK{ZYP0JIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDheEBIOSCyaHHz[S=> M2C1blI1PDF5NU[2
MCF7 M{DTb2tqdmG|ZTDBd5NigQ>? MVW1JO69VQ>? NY\qU3V2OjRiaB?= NEKxdldFVVOR M{\0eWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgR2RMPC:leXPsbY5FOSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHKndHnuc4Jt[XO2b33hJJBpd3OyaH;yfYxifGmxbjDheEBU\XJ5OEC= NWXqXFFMOjR2MUe1OlY>
MDA-MB-231 MXHLbY5ie2ViQYPzZZk> MXO1JO69VQ>? MXmyOEBp M3vCVmROW09? NVvadncxUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBETEt2L3P5Z4xqdkRzIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZicnX0bY5w[myjc4TvcYEheGixc4Doc5J6dGG2aX;uJIF1KFOncke4NC=> MojjNlQ1OTd3Nk[=
MDA-MB-231 M1P5OGZ2dmO2aX;uJGF{e2G7 NIfuRVgyNTFyIN88US=> MmXTNlQhcA>? NYPxO5RvTE2VTx?= Mn\6[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{BRSVKSIHPs[YF3[Wen MXiyOFQyPzV4Nh?=
MCF7 NULGcGdFTnWwY4Tpc44hSXO|YYm= MYexMVExKM7:TR?= M1npVlI1KGh? M3rmfGROW09? NYfSVVRl\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyCSQWLQJINt\WG4YXfl NFf5T3MzPDRzN{W2Oi=>
MDA-MB-231 M4TrUWZ2dmO2aX;uJGF{e2G7 NF36cpIxNjVvMTFOwG0> MXq0PEBp MXXEUXNQ NETYTWlp[XNibn:gR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JJN2[i2JMTDwbIF{\Q>? Mk\aNlQ1OTd3Nk[=
MCF7 M1\uWWZ2dmO2aX;uJGF{e2G7 NVLEfGFYOC53LUGg{txO NVH6XXJzPDhiaB?= M4TIT2ROW09? NGnmcIxp[XNibn:gR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JJN2[i2JMTDwbIF{\Q>? NEm1TFIzPDRzN{W2Oi=>
697 MkfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nQb2lEPTB;MUS4MlM5KG6P MUnTRW5ITVJ?
P12-ICHIKAWA M3rkU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTiTWM2OD17Nj6wOEBvVQ>? MWHTRW5ITVJ?
NB69 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTF4MT64JI5O MlTIV2FPT0WU
EoL-1 M3zBTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvuTWM2OD1zOEeuNlYhdk1? Mn\UV2FPT0WU
BHT-101 NXrSfGtlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTF7OD6yOUBvVQ>? MXHTRW5ITVJ?
SK-NEP-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DDV2lEPTB;MkKwMlAzKG6P MULTRW5ITVJ?
MHH-NB-11 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvoSWZKSzVyPUKyNE4yQSCwTR?= NIDMZmdUSU6JRWK=
AsPC-1 NVL4PJZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\vOGlEPTB;MkWyMlU{KG6P MVHTRW5ITVJ?
ES1 M3naNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUf3d3hKUUN3ME2yOVYvOjVibl2= MXfTRW5ITVJ?
LAMA-84 NWnFWHlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTJ3OD6xPUBvVQ>? M2r0b3NCVkeHUh?=
MOLT-16 Mk[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTJ3OD60PUBvVQ>? MoDqV2FPT0WU
ES7 MmT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPZcWpKSzVyPUK3N{4xQSCwTR?= NYrUWI1xW0GQR1XS
KY821 MnLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTNzND6xJI5O NWLaTZhiW0GQR1XS
RT-112 NY\uZVBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUW3OWg4UUN3ME2zNlEvODVibl2= M3;2WHNCVkeHUh?=
HL-60 NIDycW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfDVFJuUUN3ME2zOFAvPjZibl2= NXfqW2lHW0GQR1XS
MOLT-4 NGPuOldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIO0TndKSzVyPUO0OU4yOyCwTR?= NXHVZYdTW0GQR1XS
KARPAS-45 Mn;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vyUmlEPTB;M{e2MlE3KG6P NHzzPXdUSU6JRWK=
SK-N-AS MkDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTN6Nz64N{BvVQ>? M4S5e3NCVkeHUh?=
CTB-1 Mk\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\0O4lOUUN3ME20NFUvODJibl2= MUTTRW5ITVJ?
NKM-1 NWrPZ3FZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUOyNoR1UUN3ME20NVEvQDlibl2= MV7TRW5ITVJ?
HTC-C3 NFTHVnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIK0U5BKSzVyPUSzNk46PSCwTR?= MYXTRW5ITVJ?
BE-13 MlXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzIU5RKSzVyPUS0OE4zPyCwTR?= MUDTRW5ITVJ?
KOSC-2 NYHSTIV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHG2doxKSzVyPUS2Ok46KG6P M{jTRnNCVkeHUh?=
NB14 NHHtbGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlS3TWM2OD12OEOuOVghdk1? MkT0V2FPT0WU
CAL-27 Ml:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHTW2V4UUN3ME20PVQvPTlibl2= M1i3SXNCVkeHUh?=
H9 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fJU2lEPTB;NEm1MlQ{KG6P NYPxS21ZW0GQR1XS
RS4-11 MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPITWM2OD13MESuO|Mhdk1? MlXKV2FPT0WU
PA-1 NV\Ofo5oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTVyOT64OkBvVQ>? NVnm[HQ1W0GQR1XS
MV-4-11 MmfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonWTWM2OD13MUOuPFUhdk1? NUD6TmpoW0GQR1XS
OS-RC-2 NH;KNnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTV{MT62NkBvVQ>? M4DFd3NCVkeHUh?=
RPMI-8226 NFno[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTV{Nj64OkBvVQ>? MnvYV2FPT0WU
HGC-27 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWL4cpdCUUN3ME21OlQvQTlibl2= M4L2cHNCVkeHUh?=
CHP-212 Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDBRZY2UUN3ME21PVMvPTlibl2= MULTRW5ITVJ?
NB10 M{j5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrEN2pKSzVyPUW5PU4yQCCwTR?= M4fVenNCVkeHUh?=
HH M3fvOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HPcWlEPTB;NUm5MlQ{KG6P NHPzfXlUSU6JRWK=
EW-16 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nEUWlEPTB;NkCzMlUzKG6P MlXhV2FPT0WU
ES8 NH7sVpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1yyW2lEPTB;NkC1MlIyKG6P MnXUV2FPT0WU
HAL-01 NHrldldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVS1SldLUUN3ME22NFUvPjdibl2= MVTTRW5ITVJ?
A204 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\LNZBKSzVyPU[zN{46OSCwTR?= MnnyV2FPT0WU
MHH-PREB-1 NEDOb2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2CyWWlEPTB;NkO2Mlk6KG6P NHzZfGdUSU6JRWK=
EM-2 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTVXZZKSzVyPU[1NE43PCCwTR?= MWXTRW5ITVJ?
BV-173 NVPifXRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3y[IxKSzVyPU[1Nk41QCCwTR?= M3;hNXNCVkeHUh?=
ONS-76 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfS[JFKSzVyPU[3O{45OiCwTR?= NUnxSmRuW0GQR1XS
KM-H2 NVfIN5hqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTZ7NT61OEBvVQ>? M4TtVnNCVkeHUh?=
D-263MG MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDBTWM2OD15MUeuNVIhdk1? MkTnV2FPT0WU
ES3 MkfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHRcmtXUUN3ME23NlgvQTNibl2= M2j5N3NCVkeHUh?=
VA-ES-BJ NVfEZ2Z7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTuTWM2OD15M{KuNlchdk1? NVrYdZd2W0GQR1XS
NBsusSR M2ixVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mli5TWM2OD15NEKuPVkhdk1? NHLu[GZUSU6JRWK=
NCI-H520 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrNUWVKSzVyPUe0Ok42OiCwTR?= MXnTRW5ITVJ?
ES5 M33Lb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13Jd2lEPTB;N{WyMlghdk1? M4jnPXNCVkeHUh?=
T-24 M2TZbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoC0TWM2OD15N{iuO|Ehdk1? NUPXUHBjW0GQR1XS
SW962 MoLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTHTWM2OD16MEiuOlMhdk1? NHm4fFlUSU6JRWK=
EW-3 M4fBeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRThyOD63OkBvVQ>? MkHyV2FPT0WU
RXF393 M1;OZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\xfmFKSzVyPUixNk44QSCwTR?= NGfBcZdUSU6JRWK=
U251 NGT4dWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVv0NZBVUUN3ME24NVMvQDhibl2= NYPXXpB{W0GQR1XS
CAMA-1 NWrvb|ZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\OVHJKSzVyPUizN{46PCCwTR?= NUGzOVJHW0GQR1XS
JVM-3 MoXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnTdJZKSzVyPUi1NU44QCCwTR?= NYP1PVl5W0GQR1XS
COLO-800 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvkfW44UUN3ME24PVcvPzhibl2= NULUfoZ[W0GQR1XS
OVCAR-5 MnHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3uxb2lEPTB;OUCwMlEhdk1? MlzMV2FPT0WU
LB1047-RCC M4q4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTl{Nz61OkBvVQ>? NU\OPHI3W0GQR1XS
SW954 NGDwcm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nC[GlEPTB;OUK5MlQyKG6P MnXQV2FPT0WU
J-RT3-T3-5 NX7l[ndRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;L[5Q5UUN3ME25N|YvODZibl2= MXfTRW5ITVJ?
Mewo MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF63coJKSzVyPUmzOk43KG6P MlvBV2FPT0WU
NCI-H1770 NUjKVY1kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn22TWM2OD17NECuOVUhdk1? NIDIfZhUSU6JRWK=
HO-1-N-1 MmXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1j3SWlEPTB;OU[yMlgyKG6P NGn5RYRUSU6JRWK=
HSC-3 NUXOfI96T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzQcJpKSzVyPUm2Ok41QCCwTR?= NHXpdY5USU6JRWK=
TYK-nu MlL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HlOGlEPTB;OUm4MlI2KG6P NV;vfHZVW0GQR1XS
KYSE-150 NYDYNYtXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXLTWM2OD1zLkCwNFc3KM7:TR?= NHfwdYFUSU6JRWK=
SN12C NXzSR5Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M123bGlEPTB;MT6wNFg4PSEQvF2= NUD1Vlc4W0GQR1XS
MOLT-13 MorjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\WUWlEPTB;MT6wNVQzOSEQvF2= M1\1XHNCVkeHUh?=
TE-11 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4j5W2lEPTB;MT6wOFgyOiEQvF2= M2HiOHNCVkeHUh?=
DB MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTFwMEeyO|Mh|ryP MWnTRW5ITVJ?
CAL-39 Mn;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIGzeIhKSzVyPUGuNFc2OjJizszN NHTtV|RUSU6JRWK=
A3-KAW M1PudWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPuWopKSzVyPUGuNFg1ODhizszN MVXTRW5ITVJ?
CHP-134 NHH2SmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGGzNHJKSzVyPUGuNVE5ODdizszN NVrSWnJvW0GQR1XS
TGW NHS3c2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX[2NVV1UUN3ME2xMlEzOzl3IN88US=> NHnSb4ZUSU6JRWK=
QIMR-WIL M2TOUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDj[4lKSzVyPUGuNVMyOzRizszN NFHRVIxUSU6JRWK=
NCI-SNU-1 MnOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTFwMU[zOVQh|ryP NFP5SHRUSU6JRWK=
CGTH-W-1 NFPVeFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGiwR|JKSzVyPUGuNVcyQDZizszN NH[4PXNUSU6JRWK=
MHH-ES-1 MljTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrITWM2OD1zLkG3PVg3KM7:TR?= NVu5T3BCW0GQR1XS
LB2241-RCC NWLLNmxkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDZTYRKSzVyPUGuNVg3OiEQvF2= MXvTRW5ITVJ?
ML-2 NGPrVFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljGTWM2OD1zLkKwO|M1KM7:TR?= M{XuV3NCVkeHUh?=
COR-L23 M2fuc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTFwMkK5N|Mh|ryP Ml3VV2FPT0WU
BFTC-905 MoHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrE[4ZKSzVyPUGuNlQzPjdizszN MUHTRW5ITVJ?
Hs-578-T MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHaS4dKSzVyPUGuNlU5OTdizszN MoXWV2FPT0WU
KG-1 M3j6WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoC3TWM2OD1zLkK2Olg3KM7:TR?= NV;IcW11W0GQR1XS
HEL M{LoT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTFwMkmzN|gh|ryP M1PMenNCVkeHUh?=
A549 M2Ly[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnO3TWM2OD1zLkK5N|k6KM7:TR?= NVLMeHd4W0GQR1XS
COLO-741 MonSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfOTWM2OD1zLkOyNFg6KM7:TR?= MnfnV2FPT0WU
PC-3 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLmTWM2OD1zLkO1NlIyKM7:TR?= M2PaSnNCVkeHUh?=
HOS MmnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXWcI5KSzVyPUGuN|UzQTZizszN NW\STmk{W0GQR1XS
HT-1080 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTFwM{e1NVkh|ryP MmfqV2FPT0WU
TE-8 NFruNGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXFOnVKSzVyPUGuOFE4PzRizszN MkntV2FPT0WU
BHY Ml\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;nZYZKSzVyPUGuOFY6OjNizszN M2rmS3NCVkeHUh?=
BB65-RCC MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHT3SHFKSzVyPUGuOVA2OjhizszN Ml;SV2FPT0WU
HN MojtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXsTWM2OD1zLkW0NFcyKM7:TR?= NGD1SXpUSU6JRWK=
NCI-H441 MnrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmX6TWM2OD1zLkW0PVA4KM7:TR?= Mo\kV2FPT0WU
RPMI-8866 NX\RXmpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTFwNUi1NFch|ryP MlzlV2FPT0WU
CAL-62 Mkm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3jS2FxUUN3ME2xMlYxQDZ{IN88US=> NHnsWmFUSU6JRWK=
MG-63 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPyTWM2OD1zLk[xPFE{KM7:TR?= NIqzNZpUSU6JRWK=
SK-LU-1 M3Pkfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknETWM2OD1zLk[yNVUzKM7:TR?= M1jqdnNCVkeHUh?=
BCPAP NVzMWXBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfU[lgzUUN3ME2xMlY3PDV5IN88US=> MYjTRW5ITVJ?
22RV1 NVXP[mlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTFwNke4OFMh|ryP MW\TRW5ITVJ?
T47D MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXLVpR4UUN3ME2xMlY5ODZzIN88US=> MXrTRW5ITVJ?
MSTO-211H M3TKW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\UUmNVUUN3ME2xMlY6PjB|IN88US=> MXrTRW5ITVJ?
DEL MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7NTWM2OD1zLkewNlc{KM7:TR?= NFHISmhUSU6JRWK=
H4 M1\ITGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;LWplKSzVyPUGuO|MzOTJizszN NV;BRoRNW0GQR1XS
CAL-51 M{PKT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTFwN{S4OVUh|ryP MmLvV2FPT0WU
ABC-1 MkfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3T6PWlEPTB;MT63PFU5OiEQvF2= M37vR3NCVkeHUh?=
MZ2-MEL M3fHfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPUXm5LUUN3ME2xMlc6PTR{IN88US=> NWfYZpd3W0GQR1XS
YKG-1 NEfsZYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NED2[2NKSzVyPUGuPFExPjFizszN MoLXV2FPT0WU
KM12 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{f3U2lEPTB;MT64NVYxOiEQvF2= M1nxdnNCVkeHUh?=
L-363 M122emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rV[2lEPTB;MT64O|QyOiEQvF2= NGjoRWdUSU6JRWK=
KU812 M3rPXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jXZ2lEPTB;MT64PVI5OiEQvF2= NWHxOY1tW0GQR1XS
LOXIMVI MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTFwOUGyNlgh|ryP M3:4Z3NCVkeHUh?=
G-401 NEXaTZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXKcJpRUUN3ME2xMlkzPDJ6IN88US=> M2qzT3NCVkeHUh?=
SW780 NULlTFBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTFwOU[yOFYh|ryP NVfLTZJ[W0GQR1XS
SW872 NFXx[GVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUC2eocxUUN3ME2xMlk5OzNizszN NFH2VJRUSU6JRWK=
NB7 Mk\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1n1NWlEPTB;MT65PVMzOyEQvF2= M2rn[HNCVkeHUh?=
T98G MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnK[ot3UUN3ME2yMlAxPjZ4IN88US=> NFHh[XlUSU6JRWK=
SW1710 NGjEemdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4m5VmlEPTB;Mj6wOlk1PSEQvF2= NEXyUmpUSU6JRWK=
NCI-H1573 M1\MXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTJwMEeyPVgh|ryP MmLCV2FPT0WU
KE-37 M4\vfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfGd2JPUUN3ME2yMlA5QTVzIN88US=> NYrNdYpwW0GQR1XS
786-0 NISye2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfk[2pOUUN3ME2yMlE2PDN7IN88US=> MkW0V2FPT0WU
SAS NWTlO2ZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\ERVRLUUN3ME2yMlIxOzd2IN88US=> MUHTRW5ITVJ?
CAL-54 M1z4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmG5TWM2OD1{LkKwOFE{KM7:TR?= M2HHPXNCVkeHUh?=
SF268 Mlz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3uTWM2OD1{LkKzNVIzKM7:TR?= M3\ibnNCVkeHUh?=
SW620 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PCfmlEPTB;Mj6yOlE3QSEQvF2= MXvTRW5ITVJ?
MN-60 Mo\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTJwM{GwOkDPxE1? NEfmb4FUSU6JRWK=
EFO-27 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTJwM{KwOVgh|ryP M3HGOXNCVkeHUh?=
NCI-H747 M1i4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonSTWM2OD1{LkOyNVk6KM7:TR?= NITVN|lUSU6JRWK=
HCC2218 M1f0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTJwM{WzO|Qh|ryP NFrDO3VUSU6JRWK=
MIA-PaCa-2 NYjTdWtxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\zXmlKSzVyPUKuN|Y1OzdizszN NVPwdW1tW0GQR1XS
SJSA-1 M2PyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HKb2lEPTB;Mj6zO|c6PiEQvF2= MkfiV2FPT0WU
RKO MkfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLQTWM2OD1{LkO4OFk3KM7:TR?= MVfTRW5ITVJ?
NB6 NHr5UZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnFUoNKSzVyPUKuOFA{PzRizszN NHrMdXhUSU6JRWK=
ES4 MoG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37QSWlEPTB;Mj60OVQzOiEQvF2= MlHqV2FPT0WU
EGI-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTJwNE[4PFMh|ryP NFXuZ2VUSU6JRWK=
CTV-1 NWLhTGFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkm0TWM2OD1{LkWyO|c{KM7:TR?= MmTZV2FPT0WU
NCI-H1355 NWi4TYZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTJwNUW5OVEh|ryP NFrIS2VUSU6JRWK=
GT3TKB MmjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;Id|k6UUN3ME2yMlU6OTl7IN88US=> Mm\EV2FPT0WU
SK-HEP-1 M3zXVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPXRnFKSzVyPUKuOVkzPjZizszN NWTrXVNZW0GQR1XS
GAMG NWDUXG1KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TmXGlEPTB;Mj61PVM6PCEQvF2= M4Sz[3NCVkeHUh?=
SK-MES-1 NYP3V285T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjqVoxUUUN3ME2yMlYyQDB|IN88US=> M4DtXHNCVkeHUh?=
RO82-W-1 NIfv[HRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHqTWM2OD1{Lk[yNFU4KM7:TR?= NIXBbHRUSU6JRWK=
ECC10 Mk\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrORlZPUUN3ME2yMlcxOjB4IN88US=> M4rBTHNCVkeHUh?=
MCF7 M3nkcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnaTWM2OD1{LkexOFY1KM7:TR?= NVTGO5RmW0GQR1XS
D-283MED NFXHXYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\RUmFKSzVyPUKuO|I1OyEQvF2= M2D6VHNCVkeHUh?=
RPMI-7951 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XkXWlEPTB;Mj63OVY6PCEQvF2= NW\U[IJnW0GQR1XS
Ramos-2G6-4C10 M1fFb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTJwN{ewPVkh|ryP NFXiTFFUSU6JRWK=
KGN MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWj0fJh{UUN3ME2yMlgyQDh2IN88US=> NH7sTGxUSU6JRWK=
NUGC-3 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYWwVIJsUUN3ME2yMlgzPTB3IN88US=> MWDTRW5ITVJ?
NCI-H292 MmXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj1UG5OUUN3ME2yMlg2ODV|IN88US=> M{Dwd3NCVkeHUh?=
Becker MmP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTJwOUW4N|Ih|ryP MVjTRW5ITVJ?
NCI-H1299 M3O2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHqRmdKSzVyPUOuNFUzPjNizszN M4LFenNCVkeHUh?=
ETK-1 NXvac2ZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnW4TWM2OD1|LkC1OFMh|ryP MX\TRW5ITVJ?
TK10 MljoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXFe2tKSzVyPUOuNlAyPjVizszN Ml;DV2FPT0WU
VMRC-RCZ NUDZS3ZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\heY5KSzVyPUOuN|Y1QDhizszN MmGzV2FPT0WU
YH-13 MkLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4S4OWlEPTB;Mz60OFA4QSEQvF2= NY\i[XNmW0GQR1XS
DU-145 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTNwNE[yOlkh|ryP NGrOXGxUSU6JRWK=
SW1088 NEflUYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF:5WmJKSzVyPUOuOFc1PyEQvF2= NV7ISIJ2W0GQR1XS
HOP-92 NWTXO4M2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTNwNUCzOFIh|ryP M3TWfXNCVkeHUh?=
KP-N-YS M3n1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3UTWM2OD1|Lk[yNVM6KM7:TR?= NWj0NYxqW0GQR1XS
NCI-H460 M13IUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTNwNk[3N{DPxE1? M4HMSHNCVkeHUh?=
U-2-OS NH;tO49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIW5PYNKSzVyPUOuO|I2OzVizszN NHrkSFNUSU6JRWK=
A101D NF3WR4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIX5SGtKSzVyPUOuO|Y6OzZizszN MXHTRW5ITVJ?
MDA-MB-231 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjqV|dKSzVyPUOuPFE6PTFizszN M3TY[nNCVkeHUh?=
IST-MES1 NELUenhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHmUHZKSzVyPUOuPFMzKM7:TR?= MUfTRW5ITVJ?
COR-L105 NGD1eJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HVSmlEPTB;ND6wNVgh|ryP NIP4SHNUSU6JRWK=
NCI-H1437 NEXwNFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzudIRKSzVyPUSuNFI{ODJizszN M1rMO3NCVkeHUh?=
CAL-85-1 NHyxenBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXaNJNbUUN3ME20MlAzPDZzIN88US=> NILXXpJUSU6JRWK=
MZ1-PC M1rZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;CPWlEPTB;ND6xPFU2PiEQvF2= MYnTRW5ITVJ?
VM-CUB-1 Mle5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTRwM{GyPFQh|ryP NV[y[oEyW0GQR1XS
CHL-1 Mn\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTRwM{KxOlkh|ryP MWTTRW5ITVJ?
MDA-MB-361 M{jRPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTRwM{OxOVMh|ryP NH21NZpUSU6JRWK=
NCI-H661 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7ue4JWUUN3ME20MlUxODl{IN88US=> MUHTRW5ITVJ?
EW-11 M1S4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTRwNUKyN|Eh|ryP NFf3WIpUSU6JRWK=
BEN MljVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTRwNUK4NVUh|ryP M1X1V3NCVkeHUh?=
BFTC-909 M{n5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlqwTWM2OD12LkW2Nlc2KM7:TR?= M3rhNXNCVkeHUh?=
NCI-H2087 NUnuTWV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVX0SlByUUN3ME20MlU5OTZ2IN88US=> NVfafldQW0GQR1XS
RVH-421 M1\PeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTJU|dbUUN3ME20MlY3PjlizszN NGXlTIlUSU6JRWK=
P30-OHK MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjyW2s{UUN3ME20MlY5ODB6IN88US=> NUfKXXJzW0GQR1XS
NCI-H28 NIjQSFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7IVW45UUN3ME20MlgyPjZzIN88US=> NHjPUYhUSU6JRWK=
ES6 NXjHdFJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTRwOEOwNVYh|ryP MWXTRW5ITVJ?
769-P MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV22PYZtUUN3ME20Mlg2QTJ4IN88US=> M1G5SHNCVkeHUh?=
OE33 Mne4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTIcpE{UUN3ME20Mlg5OTZzIN88US=> M3HPcXNCVkeHUh?=
SW982 NEHnSGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPM[XBKSzVyPUSuPVUxPjFizszN MlvyV2FPT0WU
A388 NUnDSGhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3LTWM2OD13LkCyPVg{KM7:TR?= NXW0dpB3W0GQR1XS
TI-73 M3nofWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnJ[|VKSzVyPUWuNFYyQTRizszN NYDyZZl[W0GQR1XS
HCT-116 MnTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\yR5hQUUN3ME21MlA6QDh7IN88US=> NIfRO5lUSU6JRWK=
HuP-T3 NILvXFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrxNIVQUUN3ME21MlE5PzB7IN88US=> NI\D[ZlUSU6JRWK=
G-402 M1LITmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LDNWlEPTB;NT6xPVQyPiEQvF2= NYXmU3FlW0GQR1XS
NCI-H1792 NXf1ZY9QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzBNJBTUUN3ME21MlI1PjJ{IN88US=> NEL5N4JUSU6JRWK=
NCI-H209 NI[2b|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIS0dYtKSzVyPUWuNlU6PDJizszN Mn7hV2FPT0WU
NCI-H1650 MojjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILQbpNKSzVyPUWuN|A3OzRizszN MUPTRW5ITVJ?
LCLC-97TM1 NHzpSYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTVwM{G4NFgh|ryP M2X6e3NCVkeHUh?=
S-117 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGf1ZYpKSzVyPUWuN|Y6PzZizszN NFvobJdUSU6JRWK=
GI-ME-N M4XQdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnuSI9KSzVyPUWuN|k3QDFizszN NHnpcpBUSU6JRWK=
NCI-H2122 MnPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTVwNEmzPVch|ryP M{P2WnNCVkeHUh?=
NCI-H1793 NX6ydFJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIP0fVNKSzVyPUWuOlc2QTNizszN NUj2TXhKW0GQR1XS
C2BBe1 MoDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVO4PVQ1UUN3ME21MlcxODh6IN88US=> MVfTRW5ITVJ?
TE-12 M4Pld2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13IVGlEPTB;NT64NFU2PiEQvF2= M3rxbHNCVkeHUh?=
LCLC-103H NHTKN2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXJ[2dKSzVyPUWuPVE4KM7:TR?= MXjTRW5ITVJ?
A673 NFzYZYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXHRVBOUUN3ME21MlkyQTN{IN88US=> MmHhV2FPT0WU
BB30-HNC MnPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGq2SYVKSzVyPUWuPVg{PiEQvF2= MYDTRW5ITVJ?
SF295 NHjmWo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjxe3pKSzVyPU[uNFA1OjJizszN NEPuTJVUSU6JRWK=
KU-19-19 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoP2TWM2OD14LkCxO|MyKM7:TR?= MUXTRW5ITVJ?
CFPAC-1 NGTKb3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkP2TWM2OD14LkC0OFQ{KM7:TR?= M1fXPHNCVkeHUh?=
LoVo MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnqVZRSUUN3ME22MlA2ODZ|IN88US=> M1TrUHNCVkeHUh?=
8505C NYfRT4RmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jrcGlEPTB;Nj6wO|U4OyEQvF2= M2\hb3NCVkeHUh?=
GMS-10 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\DWYtKSzVyPU[uNVUxODJizszN Mnn3V2FPT0WU
Ca9-22 NYHSdm13T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\rb4hKSzVyPU[uNVY4OSEQvF2= MVvTRW5ITVJ?
DOK NUj4c|ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHm5N3FKSzVyPU[uNlIxPzJizszN NW[wfJppW0GQR1XS
FADU NV3ONGV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vVNmlEPTB;Nj6yOlA{QSEQvF2= NFHQNXdUSU6JRWK=
BxPC-3 MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\OblBPUUN3ME22MlI4OzJizszN NFH1XIdUSU6JRWK=
CAL-33 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33iUGlEPTB;Nj6yPVIxOSEQvF2= NGrhfWtUSU6JRWK=
SHP-77 MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjUZllKSzVyPU[uN|E2OTJizszN MVLTRW5ITVJ?
LXF-289 M2[4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTZwM{O0OVUh|ryP MkHWV2FPT0WU
GB-1 M1W5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;RNnNKSzVyPU[uN|gzKM7:TR?= NEDGUJZUSU6JRWK=
KS-1 MoH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTZwM{i0OFch|ryP MoezV2FPT0WU
D-502MG MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DrNGlEPTB;Nj60NlM4PiEQvF2= NW[zVmF4W0GQR1XS
LAN-6 MlnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHYTWM2OD14LkWxNFI{KM7:TR?= MWTTRW5ITVJ?
H-EMC-SS NXPBSlRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TNUmlEPTB;Nj61OlE1PyEQvF2= M{fvRnNCVkeHUh?=
LC-2-ad MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTZwNkCwO|Yh|ryP NG\DVIpUSU6JRWK=
NCI-H1693 Ml;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvCTWM2OD14Lk[yNlE2KM7:TR?= M1nZO3NCVkeHUh?=
SK-N-FI MmrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\odWlEPTB;Nj63OVA1PCEQvF2= NYr6dXV2W0GQR1XS
D-423MG Mn;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnwPGFKSzVyPU[uO|YyOTdizszN MlrEV2FPT0WU
KNS-42 M13KbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTHTWM2OD14Lke4NVk4KM7:TR?= M4nwdXNCVkeHUh?=
GCT NIC5UJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUS3[lBqUUN3ME22Mlk{QCEQvF2= MXnTRW5ITVJ?
DSH1 NUH4WVkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXCRpl2UUN3ME23MlA3OzNizszN M1;KNnNCVkeHUh?=
D-247MG NID1VlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTdwMEe4PFEh|ryP MmjFV2FPT0WU
NCI-SNU-5 NGHM[o9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLRNmk5UUN3ME23MlE5OzdzIN88US=> MmnFV2FPT0WU
TE-6 MlK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnpNGRKSzVyPUeuNlA3ODFizszN M2W3VHNCVkeHUh?=
NOMO-1 M3PqXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{[wUmlEPTB;Nz6yNlEzPyEQvF2= NYXhSIZ{W0GQR1XS
NB17 NFjW[pFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\IUGdKSzVyPUeuN|A{ODlizszN M3zlTnNCVkeHUh?=
EW-22 M1rIO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLBOW1kUUN3ME23MlM1OzR6IN88US=> MlPuV2FPT0WU
EW-13 NEX4e5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYW4V3llUUN3ME23MlM2OTZ{IN88US=> M1\hUnNCVkeHUh?=
DOHH-2 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HJbWlEPTB;Nz60OFAzKM7:TR?= NH7QUWtUSU6JRWK=
TGBC1TKB NH\jdllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTdwNEm4PVkh|ryP NF21N|FUSU6JRWK=
GR-ST NW\jTZlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDCTWM2OD15LkWyOVk1KM7:TR?= MlLPV2FPT0WU
KYSE-520 NXHMV2x2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DGOmlEPTB;Nz61OVUyPSEQvF2= NWHSRlZrW0GQR1XS
CAPAN-1 NWH4Umo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlK0TWM2OD15LkW5OVEh|ryP M33iWHNCVkeHUh?=
HCE-4 M4jOc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHmbWlCUUN3ME23MlYzOjd7IN88US=> MkXMV2FPT0WU
MLMA M{m3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWj4SXlPUUN3ME23MlYzQTV5IN88US=> NIq3bVZUSU6JRWK=
HT-144 NYrsWZA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfId5pKSzVyPUeuOlU{PjhizszN NGqzS25USU6JRWK=
KYSE-180 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHTWWFtUUN3ME23MlcyOTZ7IN88US=> M{X1RXNCVkeHUh?=
TE-5 NWjCcHRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3eze2lEPTB;Nz65OVk4OSEQvF2= MUPTRW5ITVJ?
IGROV-1 MljWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXaboNKSzVyPUeuPVg2PTFizszN MoP5V2FPT0WU
NCI-H1581 M3zjcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFK3PJJKSzVyPUiuNFEzKM7:TR?= MojUV2FPT0WU
SW1990 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRThwMES2OVkh|ryP Mn7VV2FPT0WU
EFM-19 M1jiVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLNZXF2UUN3ME24MlA5PTR3IN88US=> MWfTRW5ITVJ?
OGR-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fGPWlEPTB;OD60N|AzOyEQvF2= NIS3NZVUSU6JRWK=
U-118-MG NIXvSYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\UXINKSzVyPUiuOFM1PjNizszN NUnOU5J3W0GQR1XS
SK-OV-3 NVjrWJNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\0T3ZsUUN3ME24MlQ3PzZ3IN88US=> NW\LXGNzW0GQR1XS
KNS-62 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnv2TWM2OD16LkWxO|YyKM7:TR?= NGfrc|dUSU6JRWK=
GOTO NXnmc5g{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;6TWM2OD16LkW3OlM2KM7:TR?= Mn3CV2FPT0WU
8305C MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTkbIlKSzVyPUiuO|A1QDRizszN MV3TRW5ITVJ?
RPMI-2650 MlPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;CTWM2OD16LkexPVU2KM7:TR?= MX7TRW5ITVJ?
NEC8 NELMZWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELJeGZKSzVyPUiuO|Q{ODdizszN NFPBVJlUSU6JRWK=
KYSE-450 NYHMTFhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[5TWM2OD16Lki2OVQ5KM7:TR?= MUPTRW5ITVJ?
RMG-I M3K0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTlwMUSwOVgh|ryP NWLpTpdFW0GQR1XS
CAKI-1 M1zmeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{m4TWlEPTB;OT6zNVk4QSEQvF2= M{K3V3NCVkeHUh?=
KYSE-510 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzRTWM2OD17LkO1O|c5KM7:TR?= NYexVZgzW0GQR1XS
A4-Fuk M3e1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTlwM{[3NFEh|ryP MW\TRW5ITVJ?
AN3-CA NWHNe5hxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHe4PJVKSzVyPUmuOFU1PDRizszN M1fnRnNCVkeHUh?=
SK-N-DZ MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXSeo5KSzVyPUmuO|I5PDlizszN MonpV2FPT0WU
HSC-2 MkTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLWTWM2OD17Lke2OlI6KM7:TR?= M4G3ZXNCVkeHUh?=
EW-1 M2K4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLpTWM2OD17Lke5N|Y6KM7:TR?= Mne5V2FPT0WU
D-566MG MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnvTWM2OD17LkizOlY1KM7:TR?= MlvPV2FPT0WU
COLO-792 NXzjbZEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorNTWM2OD17Lkm4O|Q3KM7:TR?= MVTTRW5ITVJ?
TE-10 NIqxOpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTFyLkCzPVYh|ryP NGP4d4xUSU6JRWK=
NCI-H650 M17LS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTFyLkSyPFYh|ryP MnS1V2FPT0WU
U-266 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1L3OmlEPTB;MUCuOFU2KM7:TR?= NGPRe3pUSU6JRWK=
Detroit562 M3uydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXmTWM2OD1zMT6wOVE2KM7:TR?= NFTZT2FUSU6JRWK=
NH-12 NVj1UVJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTFzLkG0OFYh|ryP NEe4N3FUSU6JRWK=
CO-314 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;HTWM2OD1zMT6yPFQzKM7:TR?= NVTYRXQ4W0GQR1XS
IST-MEL1 M370ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7vfHN2UUN3ME2xNU42OzJ|IN88US=> M4roZ3NCVkeHUh?=
KNS-81-FD NEXFSldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXXfmVKSzVyPUGxMlU2OjdizszN NYPmdWYyW0GQR1XS
SW1463 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTFzLkW5PFkh|ryP NWPFbYp4W0GQR1XS
NCI-H23 MmHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTFzLk[1OVIh|ryP NUDUUVhTW0GQR1XS
SK-MEL-2 NVfGNHl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDS[XM4UUN3ME2xNU44OTl5IN88US=> Mor3V2FPT0WU
NB13 M2nX[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnvO3A1UUN3ME2xNk4yPDl3IN88US=> NHTESFZUSU6JRWK=
Daoy NW\3cWVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYf6RXlbUUN3ME2xNk4zQDV4IN88US=> MYXTRW5ITVJ?
NCI-H1623 M4fLSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTF{LkO4NFEh|ryP MUfTRW5ITVJ?
NMC-G1 NVvnbnpRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTnXGNRUUN3ME2xNk44OTdizszN MU\TRW5ITVJ?
DK-MG MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3niVWlEPTB;MUKuPVQ5OiEQvF2= NUTiNnNEW0GQR1XS
TCCSUP M1nyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEH0VlFKSzVyPUGzMlEzQDRizszN NUPtSXk{W0GQR1XS
SCC-15 M{f3Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nve2lEPTB;MUOuNlY2OSEQvF2= NEfaZ2FUSU6JRWK=
NOS-1 NGPhfmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPPUmhYUUN3ME2xN{4zQDl|IN88US=> NInLNotUSU6JRWK=
RH-1 MlLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTF|LkOwN|ch|ryP MmnUV2FPT0WU
SK-MEL-3 NXfCSVczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWS4Onp4UUN3ME2xN{4{PzJ6IN88US=> MmrDV2FPT0WU
NB5 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTF|LkSwOlch|ryP M{DYbXNCVkeHUh?=
SNU-387 NELtN3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojITWM2OD1zMz61NFczKM7:TR?= MVfTRW5ITVJ?
CAL-120 MmnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4T4[GlEPTB;MUOuOlcyQCEQvF2= NIXje2VUSU6JRWK=
Mo-T NUTON2JTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXHTWM2OD1zMz63NFch|ryP MVjTRW5ITVJ?
LNCaP-Clone-FGC MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTF|Lke5PVIh|ryP NXXhfXREW0GQR1XS
CAN MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTF2LkCyPFgh|ryP NVHPbVlzW0GQR1XS
SK-MEL-30 MlrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTF2LkC2N{DPxE1? MUTTRW5ITVJ?
COLO-678 NFnTZndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTF2LkC4NlIh|ryP MVLTRW5ITVJ?
SCC-9 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXPTWM2OD1zND6xNFIyKM7:TR?= NEGxWlJUSU6JRWK=
KINGS-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPmTWM2OD1zND6xOFAzKM7:TR?= Mn;vV2FPT0WU
SL-513 Mn7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkH1TWM2OD1zND6xPFch|ryP M4rHcnNCVkeHUh?=
HLE NYD4N21wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TNc2lEPTB;MUSuN|g2OiEQvF2= MVfTRW5ITVJ?
SW1573 NITudWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfBWXlKSzVyPUG0MlQ1OzVizszN MXPTRW5ITVJ?
KYSE-140 NFPaT3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\SToJKSzVyPUG0MlY{OjdizszN MXLTRW5ITVJ?
SK-PN-DW M2DG[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzpd4lLUUN3ME2xOE45ODBzIN88US=> Mle2V2FPT0WU
A253 M{fhfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XlW2lEPTB;MUWuNFYzPSEQvF2= MknjV2FPT0WU
CAL-12T NH24eHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fZNmlEPTB;MUWuOFY3OiEQvF2= M4nEU3NCVkeHUh?=
COLO-679 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoO0TWM2OD1zNT63Olg{KM7:TR?= MVTTRW5ITVJ?
UACC-257 NXn4dpc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTF4LkGyNFEh|ryP NYnTbI9[W0GQR1XS
U-87-MG NX7HeIgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXKbIRKSzVyPUG2MlM2OjNizszN NXntfZN4W0GQR1XS
HCC1806 MofTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUiycYpHUUN3ME2xOk44ODdzIN88US=> MoDuV2FPT0WU
NCI-H2170 M3XrNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Pz[mlEPTB;MUeuNlQ1QCEQvF2= NUfxZmtpW0GQR1XS
AGS MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;EPZZEUUN3ME2xO{4{QDB6IN88US=> Mo\uV2FPT0WU
MEL-HO MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTRWWJSUUN3ME2xO{44PTB|IN88US=> NVHVe|hRW0GQR1XS
SW48 M4rtTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXGy[md4UUN3ME2xO{44PzF4IN88US=> NHXLWmZUSU6JRWK=
HuP-T4 NU\pS2FiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HKUmlEPTB;MUiuNFIxPiEQvF2= MYnTRW5ITVJ?
NCI-H720 M3rjcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTF6LkG0NFIh|ryP MmXnV2FPT0WU
RCC10RGB NETqdZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\kT2lEPTB;MUiuNVY6PyEQvF2= MVXTRW5ITVJ?
HD-MY-Z NFHCVo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\veFJJUUN3ME2xPE4zOjV2IN88US=> NH[1WYNUSU6JRWK=
A427 Moi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrpTWM2OD1zOD61NFk1KM7:TR?= MVzTRW5ITVJ?
HCC2998 NEjx[ldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTF6Lk[wOVEh|ryP M2HuTHNCVkeHUh?=
EPLC-272H NVK0SYJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVWxPWtwUUN3ME2xPU4xPDN2IN88US=> NXvZV5QxW0GQR1XS
C32 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nXV2lEPTB;MUmuNFQ2KM7:TR?= M2TxRnNCVkeHUh?=
UMC-11 NHHzOYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTF7LkKxNlMh|ryP NWTwXldWW0GQR1XS
CaR-1 MkjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPtTWM2OD1zOT62PFA1KM7:TR?= M2LacnNCVkeHUh?=
KYSE-410 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPpPYNKSzVyPUG5MlkyOzlizszN M4Gx[3NCVkeHUh?=
HuCCT1 NXrMNpgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXo[lFzUUN3ME2yNE43Ojl2IN88US=> NHXwWItUSU6JRWK=
LB996-RCC NGT1XWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;lSGlEPTB;MkCuO|E3QCEQvF2= MVjTRW5ITVJ?
KYSE-70 NGDsOJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rKTmlEPTB;MkCuPFA2QSEQvF2= NFzhXWNUSU6JRWK=
CAL-72 MknYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDjfZNNUUN3ME2yNE46OTVizszN MYXTRW5ITVJ?
Capan-2 MmPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPXTWM2OD1{MT6wOFE{KM7:TR?= MWnTRW5ITVJ?
PANC-08-13 MlTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7NTIFSUUN3ME2yNU4zPTF3IN88US=> M1HZTHNCVkeHUh?=
SBC-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jTWGlEPTB;MkGuN|A5OSEQvF2= NEfwdWZUSU6JRWK=
MFM-223 NH\1NItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTJzLkOzOFIh|ryP MWPTRW5ITVJ?
BB49-HNC M2\XOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTJzLkW3NVYh|ryP NET6TI1USU6JRWK=
SH-4 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTJzLk[2NVgh|ryP M1HqfnNCVkeHUh?=
HuO9 NITiPWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTJzLkm4NlUh|ryP MXHTRW5ITVJ?
AM-38 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHSdFBKSzVyPUKyMlA1QDVizszN NV\oUY9IW0GQR1XS
A431 M1fNc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnCUVUxUUN3ME2yN{4zOTF7IN88US=> MoDCV2FPT0WU
YAPC NHzUPWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDsTHFKSzVyPUKzMlI3PTFizszN M3HKSnNCVkeHUh?=
LU-139 M3;PdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;KOolKSzVyPUKzMlQ5ODlizszN Mn7xV2FPT0WU
HEC-1 NWDyTo9mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml25TWM2OD1{Mz60PVM4KM7:TR?= NGHVVXlUSU6JRWK=
SCC-25 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\rPG9KSzVyPUK0MlMxODZizszN NX\lWnZnW0GQR1XS
HT-29 M376PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnDTWM2OD1{ND6zPFI{KM7:TR?= NIrSSXlUSU6JRWK=
PC-14 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7MTWM2OD1{ND62OVcyKM7:TR?= NXuwWppMW0GQR1XS
Calu-6 NXL6Zoo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzVPJZKSzVyPUK1MlUxPzFizszN MX\TRW5ITVJ?
SJRH30 M4OyXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TMSmlEPTB;MkWuOlQ6PiEQvF2= NFLUN3hUSU6JRWK=
ChaGo-K-1 NYDZfIhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLI[FBRUUN3ME2yOk4yPjJ7IN88US=> MnThV2FPT0WU
IA-LM M1T5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDYTWM2OD1{Nj6zOlQ2KM7:TR?= NEDkWFJUSU6JRWK=
GP5d NWj5RndkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LKcmlEPTB;Mk[uOFQ6OSEQvF2= MkDyV2FPT0WU
NCI-H2291 M4rHNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTJ4Lk[1OFEh|ryP NVvjTHhRW0GQR1XS
BALL-1 NIj1UnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzT[JJKSzVyPUK2Mlk{QTdizszN MUPTRW5ITVJ?
HCC1954 NHzueVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTJ4Lkm4NFgh|ryP NGP0eY5USU6JRWK=
NCI-H2452 MmL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TKNmlEPTB;MkeuOFE3OyEQvF2= M2m2PHNCVkeHUh?=
LU-99A MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jDXGlEPTB;MkeuOVU5OiEQvF2= NWn3T2VbW0GQR1XS
NTERA-S-cl-D1 MkXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\qW2U6UUN3ME2yO{44Ojl7IN88US=> MVjTRW5ITVJ?
PANC-10-05 NVrn[Ic4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1n1bmlEPTB;MkeuO|c4PSEQvF2= MX\TRW5ITVJ?
NCI-H2405 M4XjXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHUcpVKSzVyPUK3Mlk{QDdizszN MVnTRW5ITVJ?
MDA-MB-415 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPOTWM2OD1{OD60NVM4KM7:TR?= MoDFV2FPT0WU
NCI-H2342 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTJ6LkWyPFEh|ryP MWrTRW5ITVJ?
TGBC24TKB NV\nfW9ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJ6LkexNVch|ryP NY\xWmNXW0GQR1XS
LU-134-A NFq4WFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{e5NmlEPTB;MkiuPVI3OSEQvF2= MUDTRW5ITVJ?
SCC-4 NGOxXo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\JTWM2OD1|MT6wOFk1KM7:TR?= MWHTRW5ITVJ?
Saos-2 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETwUYNKSzVyPUOxMlk{ODZizszN NGnjRotUSU6JRWK=
RERF-LC-MS NYnWWpo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XDTGlEPTB;M{KuPFI{OSEQvF2= M2DuSXNCVkeHUh?=
M14 NV7uW25wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLmfG9xUUN3ME2zNk46PzZ2IN88US=> NGDESJdUSU6JRWK=
HPAF-II NWPMTZVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPpdnlKSzVyPUOzMlUxOTFizszN NXHP[5hJW0GQR1XS
NCI-H1755 MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nrVGlEPTB;M{SuN|MxPSEQvF2= MVnTRW5ITVJ?
D-392MG NXqwd5NOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4n4VGlEPTB;M{WuPFY4PCEQvF2= Ml3EV2FPT0WU
A704 NGWyPIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2P2Z2lEPTB;M{[uNFQzPyEQvF2= MlTZV2FPT0WU
CP50-MEL-B NGfzWGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTiTWM2OD1|Nj6xPVEyKM7:TR?= M2jPU3NCVkeHUh?=
EW-18 Mn;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHaTWM2OD1|Nj60OVIh|ryP M4HWenNCVkeHUh?=
WM-115 M{HnSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXuTWM2OD1|Nj64NFk6KM7:TR?= NU\FOXJkW0GQR1XS
LU-65 NVTBSFRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTN5LkG0NVch|ryP M2WzPXNCVkeHUh?=
NCI-H1563 MmDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7GO|FVUUN3ME2zO{4zPDh2IN88US=> MWrTRW5ITVJ?
DBTRG-05MG MlHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTN6LkC2PVEh|ryP NXzaS2NoW0GQR1XS
NCI-H630 M1qyXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTN6LkS3NVQh|ryP MnewV2FPT0WU
NCI-H1155 M13BZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TMW2lEPTB;M{muNlQzKM7:TR?= NUGxeXlmW0GQR1XS
OVACR-3 Ml:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDVTWM2OD1|OT65NVk2KM7:TR?= MmTmV2FPT0WU
OAW-42 MnLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLJTWM2OD12MD60NlU5KM7:TR?= MmD4V2FPT0WU
JVM-2 MkDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTnNY1[UUN3ME20NU4zPDF3IN88US=> NITrSYdUSU6JRWK=
C3A NWCwT|lUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXqfXNWUUN3ME20NU4{PDR5IN88US=> Ml\NV2FPT0WU
HT55 NWXxOnhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnkTWM2OD12Mj6yPFQyKM7:TR?= MlLTV2FPT0WU
OVCAR-4 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTR{LkK5O|Qh|ryP NWXBSW9wW0GQR1XS
MEG-01 NYKw[mUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTpWJFKSzVyPUSyMlQ3OTZizszN M{n5U3NCVkeHUh?=
NCI-H82 NYniWIF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[0TWM2OD12Mz65PFkzKM7:TR?= NEDufJlUSU6JRWK=
JEG-3 MoLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrjbG9KSzVyPUS0Mlk1PyEQvF2= M2LJd3NCVkeHUh?=
BPH-1 NHnSR|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{e4TGlEPTB;NE[uN|k6QCEQvF2= NI\3PFRUSU6JRWK=
MPP-89 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\leIZ7UUN3ME20O{4zQDl6IN88US=> NH3yd5hUSU6JRWK=
ALL-PO NGLiNINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTR5LkSxPFgh|ryP NVnLV4dDW0GQR1XS
HT M3G3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vRN2lEPTB;NEeuOFkzKM7:TR?= MkTtV2FPT0WU
NCI-H2347 NVXtbmM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nVfGlEPTB;NEiuNFcyPSEQvF2= NYfQU21iW0GQR1XS
A2780 Mo\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\YTWM2OD12OT60NlI5KM7:TR?= MkDoV2FPT0WU
KARPAS-299 MkO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\NSlVPUUN3ME20PU42OTF7IN88US=> NW\Cc4ZYW0GQR1XS
NCI-H1651 M4Lve2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{f6e2lEPTB;NEmuPFgzOSEQvF2= M1i3UHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

体内研究 150 mg/kg PD 0332991处理 MDA-MB-435移植瘤完全抑制肿瘤。在多种人类肿瘤移植瘤中,PD 0332991也显示广谱抗癌活性,通过除去血管中p-Rb和增殖Marker Ki-67,且调节基因使其处于E2F转录水平控制。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

Cdk实验:

PD0332991溶解在DMSO中。在96孔板上进行CDK 实验。通过杆状病毒感染,所有的CDK-cyclin 激酶复合体 在昆虫细胞中表达。实验底物为与GST融合的一段pRb。每孔体积为0.1 ml,包含:终浓度为20 mm Tris-HCl(pH 为7.4), 50 mmNaCl, 1 mm二硫苏糖醇, 10 mmMgCl2, 25 μm ATP (用于CDK4-cyclin D1, CDK6-cyclin D2,和CDK6-cyclin D3)或12 μm ATP (用于CDK2-cyclin E, CDK2-cyclin A, 和CDC2-cyclin B),0.25 μCi [γ-32P]ATP, 20 ng 酶, 1 μg GST·RB-Cterm, 及PD 0332991 (0.001-0.1μM)。除了[γ-32P]ATP的所有混合物加到孔中,放在搅拌器上搅拌2分钟。加入 [γ-32P]ATP开始反应, 在25 oC下温育15分钟。加入0.1 ml 20% 三氯乙酸终止反应, 在4 oC维持至少1小时,使底物沉淀。用0.2 ml 10%三氯乙酸冲洗5次,用β-计数器板测定掺入的放射性。
细胞实验:

[1]

+ 展开
  • Cell lines: MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM,和K562细胞
  • Concentrations: 0.01-1 μM
  • Incubation Time: 24小时
  • Method:

    肿瘤细胞包括MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM,及K562按每孔2×104个细胞接种在96孔板上,温育过夜。加入PD 0332991 (0.01-1 μM) ,37oC温育24小时。每孔加入[14C]胸甘(0.1 μCi) ,进行同位素示踪,持续72小时。用β-计数器板测定掺入的放射性。


    (Only for Reference)
动物实验:

[1]

+ 展开
  • Animal Models: 携带晚期人类肿瘤移植瘤,包括结肠-205, MDA-MB-435 乳腺癌, SF-295 恶性胶质瘤, ZR-75-1 乳腺癌, PC-3 前列腺癌, H125 肺癌, SW-620结肠癌, H23肺癌,及MDA-MB-468 乳腺癌 (Rb 阴性)的SCID鼠
  • Formulation: 溶解在乳酸钠buffer(50 mM, pH 4.0)中
  • Dosages: 0-150 mg/kg
  • Administration: 口服饲喂
    (Only for Reference)

溶解度 (25°C)

体外 Water 30 mg/mL (61.98 mM)
DMSO 3 mg/mL warmed (6.19 mM)
Ethanol Insoluble
体内 从左到右依次加入纯溶剂:
Saline
20 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 483.99
化学式

C24H29N7O2.HCl

CAS号 827022-32-2
稳定性 powder
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03007979 Not yet recruiting Breast Cancer|Breast Carcinoma|Cancer of Breast|Malignant Tumor of Breast Washington University School of Medicine February 28, 2017 Phase 2
NCT02907918 Not yet recruiting Breast Cancer|Cancer of Breast|Breast Carcinoma Washington University School of Medicine|Pfizer February 28, 2017 Phase 2
NCT01209598 Completed Sarcoma|Liposarcoma Memorial Sloan Kettering Cancer Center|Pfizer September 23, 2010 Phase 2
NCT03054363 Not yet recruiting Breast Cancer University of Colorado, Denver March 2017 Phase 1|Phase 2
NCT03024489 Not yet recruiting Head and Neck Cancer|Locally Advanced|Unresectable Mahidol University February 2017 Phase 1|Phase 2
NCT02947685 Not yet recruiting HER-2 Positive Breast Cancer|Estrogen Receptor Positive Breast Cancer Alliance Foundation Trials, LLC.|Pfizer|German Breast Group (GBG)|Fondazione Michelangelo|PrECOG, LLC.|The Australia and New Zealand Breast Cancer Trials Group (ANZBCTG)|Alliance Foundation Trials Biorepository - Washington State University|Alliance Foundation Trials Central Imaging Core Lab - Ohio State University|Mastering Breast Cancer Initiative, LLC|Mayo Clinic Statistics and Data Center|INC Research|SOLTI Breast Cancer Research Group February 2017 Phase 3

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    There are two kind of Palbociclibs available: the isethionate salt or the HCl salt. I would like to know which is the main difference between them and what are they more suitable for in terms of experiment type (cell culture or in vivo animals experiments).

  • 回答:

    This two compounds are different Palbociclib salt. S1579 is the Isethionate salt, and the S1116 is the HCl salt. you can use S1116 for oral administration while S1579 is more suitable for I.P. administration.

Related Antibodies

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

相关CDK产品

Tags: 购买Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl供应商 | 采购Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl价格 | Palbociclib (PD-0332991) HCl生产 | 订购Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID